Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan:237:106736.
doi: 10.1016/j.actatropica.2022.106736. Epub 2022 Oct 29.

Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage

Affiliations
Free article

Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage

Serena Marchi et al. Acta Trop. 2023 Jan.
Free article

Abstract

Genetic and phylogenetic studies indicated that Zika virus (ZIKV) has evolved into 2 major lineages, the African and Asian. However, ZIKV has been described as a single serotype. This study aimed at assessing the cross-neutralization between ZIKV African and Asian lineages strains. Sixthy-five samples collected in 2007 and 30 samples collected from the same subjects in 2011/2012 in West Africa and positive to neutralizing antibody against ZIKV MR-766 strain (African lineage) were tested against ZIKV H/PF/2013 strain (Asian lineage) by microneutralization assay. All samples showing neutralizing antibodies against MR-766 strain showed also neutralizing activity against H/PF/2013 strain, although with lower titers. This is consistent with about 120 amino acid differences between the two strains. Despite differences in the magnitude of neutralizing activity against different ZIKV strains, all samples showed neutralizing antibody titers considered to be protective.

Keywords: African lineage; Asian lineage; Cross-neutralization; Immunity; Zika strains; Zika virus.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest M.Z. reports consultancy for ViiV Healthcare, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Theratechnologies and Merck Sharp and Dohme and grants for his institution from ViiV Healthcare, Theratechnologies and Gilead Sciences outside the submitted work. E.M. is founder and Chief Scientific Officer of VisMederi srl.

LinkOut - more resources